Steven E Arnold, Suzanne Hendrix, Jessie Nicodemus-Johnson, Newman Knowlton, Victoria J Williams, Jeffrey M Burns, Monica Crane, Alison J McManus, Sanjeev N Vaishnavi, Zoe Arvanitakis, Judith Neugroschl, Karen Bell, Bianca A Trombetta, Becky C Carlyle, Pia Kivisäkk, Hiroko H Dodge, Rudolph E Tanzi, Patrick D Yeramian, Kent Leslie
INTRODUCTION: Sodium phenylbutyrate and taurursodiol (PB and TURSO) is hypothesized to mitigate endoplasmic reticulum stress and mitochondrial dysfunction, two of many mechanisms implicated in Alzheimer's disease (AD) pathophysiology. METHODS: The first-in-indication phase 2a PEGASUS trial was designed to gain insight into PB and TURSO effects on mechanistic targets of engagement and disease biology in AD. The primary clinical efficacy outcome was a global statistical test combining three endpoints relevant to disease trajectory (cognition [Mild/Moderate Alzheimer's Disease Composite Score], function [Functional Activities Questionnaire], and total hippocampal volume on magnetic resonance imaging)...
2024: Alzheimer's & Dementia: Translational Research & Clinical Interventions